Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Teresa Boyea"'
Autor:
Xin Li, Jianke Li, Richard Molenkamp, Andre van Vliet, Christine J. Weegink, Daphne M. Hotho, Hans-Peter Guler, Joep de Bruijne, Harry L.A. Janssen, A. Marie O'Farrell, Teresa Boyea, Michele Bracken, Hendrik W. Reesink, Robert J. de Knegt, Jeroen van de Wetering de Rooij, Janke Schinkel, David Campbell
Publikováno v:
Antiviral therapy, 17(2), 365-375. International Medical Press Ltd
Antiviral Therapy, 17(2), 365-375. International Medical Press Ltd
Antiviral Therapy, 17(2), 365-375. International Medical Press Ltd
Background PHX1766 is a novel HCV NS3/4 protease inhibitor with robust potency and high selectivity in replicon studies (50% maximal effective concentration 8 nM). Two clinical trials investigated the safety, tolerability, pharmacokinetics and antivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e4536e7309611d74c0d1d4394da0c6d
https://pure.eur.nl/en/publications/30b87d3c-5c66-4068-9ee3-f0fb85cebe5a
https://pure.eur.nl/en/publications/30b87d3c-5c66-4068-9ee3-f0fb85cebe5a
Autor:
Kirsti Klemm, Sherwyn Schwartz, Julie M. Cherrington, Hans-Peter Guler, Jianke Li, Teresa Boyea, A. Marie O'Farrell
Publikováno v:
Current Medical Research and Opinion. 26:2003-2010
Dutogliptin is a novel, orally available, potent, and selective DPP4 inhibitor that improves glycemic control in type 2 diabetic patients. The objective of this study was to evaluate the potential pharmacokinetic and pharmacodynamic interactions, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fb9ce6200958727f75ccd1f0adf9ae1
https://doi.org/10.1185/03007995.2010.491266
https://doi.org/10.1185/03007995.2010.491266
Autor:
Jianke Li, Kirsti Klemm, A. Marie O'Farrell, Hans-Peter Guler, Julie M. Cherrington, Sherwyn Schwartz, Teresa Boyea
Publikováno v:
Current Medical Research & Opinion; Jan2010, Vol. 26 Issue 8, p2003-2010, 8p